XOMA News and Press, XOMA Corporation From 09/06/23

EMERYVILLE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, will present a company update at the H.C. Wainwright 25 th Annual Global Investment Conference on Tuesday, September 12, 202...

2023-09-01 07:30:00 ET Summary XOMA Corporation helps fund drug research and clinical trials in exchange for payments. Developing a new drug is expensive and high-risk, with a 90% failure rate in clinical trials. Along with its no-dividend Common, XOMA offers two preferred stocks ...

2023-08-08 07:53:05 ET XOMA press release ( NASDAQ: XOMA ): Q2 GAAP EPS of -$0.59. Revenue of $1.7M (+70.0% Y/Y). For further details see: XOMA GAAP EPS of -$0.59, revenue of $1.7M

Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and a Phase 2 asset Two portfolio assets are now generating cash flows from commercial sales Company expects at least one partner to file a New Drug Applicati...

2023-06-26 03:13:41 ET The biotech royalty aggregator, XOMA ( NASDAQ: XOMA ) has been added to the Russell 2000 and Russell 3000 Indexes following its annual reconstitution, which took effect after the U.S. markets close on June 23, 2023. XOMA is a...

EMERYVILLE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol, an oral therapeutic for Niemann-Pick disease type C, and aldoxorubicin, an albumi...

2023-05-24 13:57:04 ET The Russell 3000 index will have a new look on June 26, after the market opens, when 286 securities will be added and 179 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added an...

2023-05-09 07:42:46 ET XOMA press release ( NASDAQ: XOMA ): Q1 GAAP EPS of -$0.98. Revenue of $0.44M (-85.8% Y/Y). For further details see: XOMA GAAP EPS of -$0.98, revenue of $0.44M

First quarter with incoming cashflows from two commercial assets Completed first royalty asset acquisition under new leadership EMERYVILLE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2023 fin...

EMERYVILLE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat at the H.C. Wainwright BioConnect Investor Confere...